Last updated: March 1, 2023
Sponsor: Hannover Medical School
Overall Status: Active - Recruiting
Phase
N/A
Condition
Heart Transplantation
Treatment
N/AClinical Study ID
NCT03687723
OCS-Heart-2016
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria: All recipients of heart transplantation with Use of the OCS™ Heart
Exclusion
Exclusion Criteria: Donor Hearts
- Presence of coronary heart diseases
- acute myocardial infarction
- Presence of heart valve disease (Stenosis or Insufficiency > first degree)
- Presence of left ventricular hypertrophy (septum and posterior wall thickness >1.7 cm)
- State of shock of donor (MAP <60 mmHg, CVP >15, PCWP >15 mmHg) with use of Dobutamine >10 ug/kg/min and/or Norepinephrine > 0.5 ug/kg/min or Epinephrine > 0.2 ug/kg/min
- irreversible persistant pulmonary hypertrophy, defined as transpulmonary gradient >15mmHg of the recipient
Study Design
Total Participants: 100
Study Start date:
October 01, 2016
Estimated Completion Date:
March 31, 2025
Study Description
Connect with a study center
Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery
Hannover,
GermanyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.